During IR or DM2 the risk to develop non-alcoholic fatty liver increases due to inflammatory factors; where nuclear factor enhancing kappa of activated B cells (NFkB) or elements of carbohydrate metabolism that affect lipogenesis like element binding protein carbohydrate response (ChREBP) stand out. The gene discussed is MLXIPL; the disease is Hepatic steatosis.